KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

West Pharmaceutical Services (WST) Shares Outstanding (2016 - 2026)

West Pharmaceutical Services has reported Shares Outstanding over the past 17 years, most recently at $70.9 million for Q1 2026.

  • Quarterly Shares Outstanding fell 5.84% to $70.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $70.9 million through Mar 2026, down 5.84% year-over-year, with the annual reading at $72.0 million for FY2025, 4.38% down from the prior year.
  • Shares Outstanding was $75.3 million for Q1 2026 at West Pharmaceutical Services, roughly flat from $75.3 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $75.3 million in Q1 2022 and troughed at $75.3 million in Q1 2022.
  • The 5-year median for Shares Outstanding is $75.3 million (2022), against an average of $75.3 million.
  • Biggest five-year swings in Shares Outstanding: changed 0.0% in 2022 and later decreased 5.84% in 2026.
  • Tracing WST's Shares Outstanding over 5 years: stood at $75.3 million in 2022, then changed by 0.0% to $75.3 million in 2023, then changed by 0.0% to $75.3 million in 2024, then dropped by 4.38% to $72.0 million in 2025, then fell by 1.53% to $70.9 million in 2026.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $70.9 million, $72.0 million, and $75.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.